**ADMA Biologics reports equity awards to Terry Kohler** ADMA Biologics, Inc. reported an insider ownership change for Terry Kohler tied to equity compensation granted on July 16, 2026. The filing describes the transaction as involving ADMA common stock and awards made under the company’s 2022 Equity Compensation Plan. The action appears to be a compensation-related grant rather than an open-market purchase or sale. Kohler received **85,130 restricted stock units**, or RSUs, on July 16, 2026. Each RSU represents a contingent right to receive **one share of ADMA common stock** upon vesting. The RSUs are scheduled to vest over four years, with vesting tied to continued service through the applicable vesting dates. No cash purchase price is described for the RSUs, which is typical for compensatory RSU grants. The filing also notes Kohler’s existing unvested RSU position. As of the transaction date, Kohler held **143,149 unvested RSUs in total**, consisting of the newly granted **85,130 RSUs** and **58,019 unvested RSUs** previously granted on **December 8, 2025**. Those earlier RSUs also vest over four years and settle into common stock upon vesting, subject to continued service. In addition to the RSUs, ADMA granted Kohler a **stock option** on July 16, 2026. The option vests over four years: **25% of the underlying shares vest on July 16, 2027**, the one-year anniversary of the grant date, and the remaining **75% vest in substantially equal monthly installments** over the following three years at a rate of **1/48th of the total option shares per month**. The option is scheduled to become fully vested on **July 16, 2030**, again subject to continued service. The provided filing text does not show the option’s share count, exercise price, transaction code, or expiration date. Overall, the Form 4 reports a new equity compensation package for Kohler, increasing his contingent ownership through RSUs and adding a long-term option award. These grants align the insider’s compensation with ADMA’s share performance over a multi-year vesting period.
Stock detail
Adma Biologics (ADMA) stock price, chart, and key data
View Adma Biologics stock price, chart movement, and headline metrics on Woodstock's stock detail page.
Stock detail
Adma Biologics
ADMA · XNAS
+$0.28 (+3.31%) past day
$8.74
Overnight $8.72 (-0.11%)
Key metrics
Earnings
Quarterly results and the next expected release
FY25 Q2
Q3
Q4
FY26 Q1
Q2
Q3
Day range
$8.19 - $8.46
Close price
$8.37
Market cap
$1.9B
P/E ratio
12.85
About the company
Adma Biologics Inc
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
Ticker holders
Review politician disclosures and insider transactions in tabs.
Holder directory
Select a heading to reorder by name, activity date, buy/sell, or displayed value.
#1Donald J Trump
republican · Executive
Market action
A concise summary of the latest filing, transaction, or market-moving item.
24/5 Trading
Act on the stock when the timing works for you.
With Woodstock, you can move from chart review to order placement in one flow. Trade eligible US stocks 24/5, even outside regular market hours.
*24-hour trading is available except during system maintenance. Some stocks are not eligible for extended-hours trading.
Download the app